Market closed
Cyclacel Pharmaceuticals Inc./$CYCC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.
Ticker
$CYCC
Sector
Trading on
Industry
Biotechnology
Headquarters
Kuala Lumpur, Malaysia
Employees
12
Website
CYCC Metrics
BasicAdvanced
$66M
-
-$2.09
0.16
-
Price and volume
Market cap
$66M
Beta
0.16
52-week high
$0.42
52-week low
$0.17
Average daily volume
4.9M
Financial strength
Current ratio
0.586
Quick ratio
0.5
Management effectiveness
Return on assets (TTM)
-116.33%
Return on equity (TTM)
1,431.01%
Valuation
Price to revenue (TTM)
39.619
Price to book
-1.3
Price to tangible book (TTM)
-1.3
Price to free cash flow (TTM)
-0.213
Growth
Revenue change (TTM)
-89.76%
Earnings per share change (TTM)
-92.17%
3-year earnings per share growth (CAGR)
-59.43%
CYCC News
AllArticlesVideos
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT
GlobeNewsWire·2 days ago
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.
GlobeNewsWire·3 days ago
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cyclacel Pharmaceuticals Inc. stock?
Cyclacel Pharmaceuticals Inc. (CYCC) has a market cap of $66M as of May 09, 2025.
What is the P/E ratio for Cyclacel Pharmaceuticals Inc. stock?
The price to earnings (P/E) ratio for Cyclacel Pharmaceuticals Inc. (CYCC) stock is 0 as of May 09, 2025.
Does Cyclacel Pharmaceuticals Inc. stock pay dividends?
No, Cyclacel Pharmaceuticals Inc. (CYCC) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Cyclacel Pharmaceuticals Inc. dividend payment date?
Cyclacel Pharmaceuticals Inc. (CYCC) stock does not pay dividends to its shareholders.
What is the beta indicator for Cyclacel Pharmaceuticals Inc.?
Cyclacel Pharmaceuticals Inc. (CYCC) has a beta rating of 0.16. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.